Biond and Sanofi Partner, Plan for Trial of Checkpoint Inhibitor BND-22

Biond and Sanofi Partner, Plan for Trial of Checkpoint Inhibitor BND-22

286472

Biond and Sanofi Partner, Plan for Trial of Checkpoint Inhibitor BND-22

Biond Biologics and Sanofi have entered into a worldwide licensing agreement to advance BND-22, a novel immune checkpoint inhibitor, into clinical testing as a potential treatment of solid tumors. An investigational new drug (IND) application, requesting that the treatment be cleared for patient trials, was recently filed with the U.S. Food and Drug Administration. If approved, a first clinical trial in advanced cancer patients is planned to begin by mid-year, the companies announced. “We are…

You must be logged in to read/download the full post.